HTG Molecular Diagnostics Announces IVD Development Agreement with Thermo Fisher Scientific

HTG Molecular Diagnostics, Inc. (Tucson, AZ, USA), a provider of instruments and reagents for molecular profiling applications, have announced that it has entered into a long-term agreement with Thermo Fisher Scientific (Waltham, MA, USA) under which HTG will have the right to develop a number of in vitro diagnostic (IVD) tests for use with Thermo Fisher’s next-generation sequencing Ion PGM Dx System.

In 2013 HTG Molecular Diagnostics commercialized its HTG Edge instrument platform and a portfolio of ribonucleic acid (RNA) assays that leverage HTG's proprietary nuclease protection chemistry. HTG's product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing.

HTG EdgeSeq system automates their novel target capture and library preparation chemistry and helps enable fast and easy use of next-generation sequencers (NGS) for microRNA (miRNA), messenger RNA (mRNA), fusions, and DNA analysis. HTG EdgeSeq system simplifies library and sample preparation for targeted sequencing enhancing productivity and ease of use. HTG EdgeSeq extraction-free chemistry also can significantly reduce sample input requirements, especially from formalin-fixed, paraffin embedded (FFPE) samples.

Timothy (TJ) B. Johnson, BS, President and Chief Executive Officer at HTG, said, “We believe the combination of HTG EdgeSeq chemistry and automation platform with the Ion Torrent next-generation sequencing (NGS) platform is a great solution for clinical sequencing workflows in molecular diagnostic laboratories. We believe this agreement will provide us important options for our planned diagnostic menu.”

Related Links:
HTG Molecular Diagnostics 
Thermo Fisher Scientific